Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_assertion type Assertion NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_head.
- NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_assertion description "[At the moment the most promising parameters for future trials and treatment decisions seem to be the plasma cell labeling index, the beta2-microglobulin and hopefully cytogenetic abnormalities that are detectable in multiple myeloma now using newer cultivation methods and fluorescence in situ hybridization in interphase plasma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_provenance.
- NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_assertion evidence source_evidence_literature NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_provenance.
- NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_assertion SIO_000772 9436931 NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_provenance.
- NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_assertion wasDerivedFrom befree-20140225 NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_provenance.
- NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_assertion wasGeneratedBy ECO_0000203 NP894059.RA9pCWBDMtsXfxQzztdOEu1Tvsmdu-MWWbT4W1ryVcXgo130_provenance.